楚天科技(300358.SZ):擬4750萬元收購楚天飛雲剩餘49.01%股權
格隆匯9月23日丨楚天科技(300358.SZ)公佈,公司擬以發行股份的方式,購買葉大進、葉田田持有的楚天飛雲合計1160.00萬元出資對應的股權,交易對價為4750.00萬元。
該次交易前,上市公司已持有楚天飛雲50.9928%股權,楚天飛雲為上市公司控股子公司;該次交易完成後,楚天飛雲將成為上市公司全資子公司,該次交易不會導致上市公司合併報表範圍發生變化。
楚天飛雲主營業務為研發、生產及銷售全自動硬膠囊充填機、藥用高純度制氮機等產品設備,該次併購有助於楚天科技拓寬產品系列。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.